Ansun Biopharma
San Diego, US · California corporation · 2 known investors
Ansun develops novel therapeutic treatments targeting viral diseases, particularly respiratory infections, through its proprietary sialic acid biology platform. The company focuses on unmet medical needs in immunocompromised and underserved patient populations.
Founders & leadership
RM
RONALD MOSSinChief Medical Officer
MA
MARK ATTEBURYinVP, Finance2014–2017
MH
MIKAEL HAVLUCIYANExecutive
Board
MC
MICHAEL CHANGBoard director
NC
Nancy ChangChairperson of the Board
AC
Allen ChaoBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$180.2M disclosed across 5 rounds · 2014–2019
▶$100MraisedNov 2020 · 19 investors · BiotechnologyRule 506(b)
▶$100MraisedNov 2020 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- DAVE CHENNDirector
- KAREN LIUDirector
- AIMIN WUDirector
- YI SHIDirector
- DONALD PAYNEDirector
- MICHAEL CHAODirector
- Yining ZhaoExecutive Officer
- MICHAEL CHANGDirector
- ALLEN CHAODirector
- NANCY CHANGExecutive Officer, Director
- Offering amount
- $100M
- Amount sold
- $100M
- Sales commissions
- $960K
- Placement agents
- China Renaissance Securities (US) Inc.
- First sale
- Jul 2019
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$67.1MraisedAug 2019 · 29 investors · OtherRule 506(b)
▶$67.1MraisedAug 2019 · 29 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Shi YiDirector
- Donald PayneDirector
- Michael ChaoDirector
- Mikael HavluciyanExecutive Officer
- Allen ChaoDirector
- Nancy ChangExecutive Officer, Director
- Aimin WuDirector
- Michael ChangDirector
- Offering amount
- $67.1M
- Amount sold
- $67.1M
- First sale
- Apr 2018
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$1.6MraisedMar 2018 · 6 investors · OtherRule 506(b)
▶$1.6MraisedMar 2018 · 6 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Nancy ChangExecutive Officer, Director
- Michael HavluciyanExecutive Officer
- Michael ChangDirector
- Allen ChaoDirector
- Offering amount
- $1.6M
- Amount sold
- $1.6M
- First sale
- Feb 2017
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$4MraisedDec 2015 · 6 investors · BiotechnologyRule 506(b)
▶$4MraisedDec 2015 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- RONALD MOSSExecutive Officer
- ALLEN CHAODirector
- MICHAEL CHANGDirector
- MARK ATTEBURYExecutive Officer
- MIKAEL HAVLUCIYANExecutive Officer
- NANCY CHANGDirector
- Offering amount
- $10M
- Amount sold
- $4M
- Proceeds to insiders
- $700K
- First sale
- Nov 2015
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$7.5MraisedMay 2014 · 7 investors · BiotechnologyRule 506(b)
▶$7.5MraisedMay 2014 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- RONALD MOSSExecutive Officer
- NANCY CHANGDirector
- ALLEN CHAODirector
- NANCY CHANGDirector
- MIKAEL HAVLUCIYANExecutive Officer
- Offering amount
- $17.9M
- Amount sold
- $7.5M
- First sale
- May 2014
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Precision For Medicine8 shared keywordsPrecision for Medicine is a contract research organization that provides clinical trial management and regulatory support for drug development programs, including oncology, hematology, cell and gene therapy, CAR-T, and radiopharmaceutical trials. It serves pharmaceutical and biotech sponsors running multinational Phase I–IV studies.
Iconplc8 shared keywordsICON plc is a global Contract Research Organization providing consulting and outsourced development services to pharmaceutical, biotechnology, medical device, and government organizations to accelerate drug and device development. The company supports clients across all phases of clinical development with integrated services spanning study design, patient recruitment, digital trial solutions, and commercialization.
Syneos Health7 shared keywordsSyneos Health is a fully integrated biopharmaceutical solutions organization that provides clinical, medical affairs, and commercial services to help pharmaceutical companies accelerate market access and patient outcomes.
Power6 shared keywordsPower builds a patient-friendly platform to discover and enroll in clinical trials, serving patients seeking access to research studies and researchers seeking to improve patient recruitment. The company operates in the healthcare technology and clinical research industry.
Companies competing with Ansun Biopharma for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Ansun Biopharma do?
- Ansun develops novel therapeutic treatments targeting viral diseases, particularly respiratory infections, through its proprietary sialic acid biology platform. The company focuses on unmet medical needs in immunocompromised and underserved patient populations.
- Who are Ansun Biopharma's investors?
- Ansun Biopharma's investors include LAV, Lilly Asia Ventures.
- How much funding has Ansun Biopharma raised?
- Ansun Biopharma has disclosed $180.2M raised across 5 rounds.
- Where is Ansun Biopharma headquartered?
- Ansun Biopharma is headquartered in San Diego, US.